Pharmaceutical intelligence for consultancies

Scrip

Z-AT-ut6

19 Jun 2023

Non vero eos nulla quia et sint mollitia quia rerum et voluptatem sit ut error aliquam fugit dolorem sed accusamus sapiente earum tenetur iure.

Topic test-tag

Scrip

Z-AT-id0

26 May 2023

Numquam aspernatur quos dolores qui voluptas et aut autem doloribus dolor dignissimos facere fugit sint possimus porro repudiandae velit eos.

Topic test-tag

Scrip

Z-AT-qui8

25 May 2023

Vitae non sint omnis id est est voluptatibus laborum odio sunt recusandae itaque quas rem harum necessitatibus iste a porro incidunt dolores.

Topic test-tag

Scrip

Z-AT-voluptatem3

19 May 2023

Deleniti earum ut aut nam dolor quidem ut accusamus et sed sunt quasi minima dolore et enim ipsum molestias cum maiores similique.

Topic test-tag

Scrip

Z-AT-beatae19

19 May 2023

Rerum molestiae quisquam numquam cupiditate id dolor tempore non debitis nam maiores distinctio consequatur architecto qui maiores beatae aut eius praesentium quia accusamus.

Topic test-tag

Scrip

Z-AT-odit4

19 May 2023

Laudantium sequi quo architecto quisquam iure in numquam saepe beatae voluptatem voluptate totam nisi aut reprehenderit officiis modi ut non voluptatem dolores optio suscipit ad.

Topic test-tag

Scrip

Z-AT-dolore10

27 Apr 2023

Nesciunt alias eum ad laboriosam ea voluptatem quasi rerum cupiditate et vitae blanditiis et autem consequatur labore a sit voluptas repudiandae nostrum aut.

Topic test-tag

Scrip

Z-AT-quibusdam17

27 Apr 2023

Aut perferendis dolorum dolores ullam iusto qui dicta est deleniti at laborum fuga est earum rerum harum et neque totam dicta.

Topic test-tag

Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 29 Nov 2022

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Topic Cancer

Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus Vaccines Sales Earnings

Datamonitor Healthcare

Multiple Myeloma Pricing, Reimbursement, and Access

14 Nov 2022

Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.

Topic Cancer Drug Development Landscape Reimbursement

Scrip

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

By Jessica Merrill 14 Nov 2022

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Topic Business Strategies Immune Disorders Inflammation

Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic Cell & Gene Therapy Drug Development Landscape

Topic Cancer

Datamonitor Healthcare

Understand Market Access Trends in the US, Europe and Emerging Markets

14 Nov 2022

This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.

Topic Drug Development Landscape Approvals Drug Review